Objective:

To evaluate the efficacy and safety of oral ICP-332 in adults with moderate to severe atopic dermatitis (AD).

Approach:

Key Findings:

• Mean EASI reductions were 78% for the 80-mg dose and 73% for the 120-mg dose, compared to 17% for placebo.
• 64% of patients in both ICP-332 groups achieved an EASI 75 response versus 8% with placebo.
• Improvements in pruritus were observed as early as day 2.

Interpretation:

ICP-332 monotherapy demonstrated significant efficacy and a favorable safety profile in treating moderate to severe AD, warranting further investigation in larger trials.

Limitations:

• Small sample size and short treatment duration limit long-term efficacy assessment.
• All participants were of Asian descent, affecting generalizability.
• No active comparators or subgroup analyses were included.

Conclusion:

The study supports the initiation of larger phase 3 trials to confirm ICP-332's effectiveness in AD treatment.

Sources:

• JAMA Dermatology
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.